

**Figure e-1.** Prevalence of MS patients seropositive for the depicted antigens before and during natalizumab treatment. **(A and B)** Prevalence of patients seropositive for antigens indicated, before (V0, dark grey bars) and after 12 months of natalizumab treatment (V12, light grey bars). Statistics: McNemar test (A and B).

